文献类型：期刊文章

作　　者：邢飞跃[1] 赵克森[1] 姜勇[1]

机构地区：[1]第一军医大学全军休克微循环重点实验室,广东广州510514

出　　处：《中国病理生理杂志》

基　　金：国家杰出青年科学基金资助项目 (3992 5 0 14 ) ;国家重点基础研究发展规划课题 (G 2 0 0 0 0 5 70 0 4 );国家自然科学基金重点项目 (No .30 0 30 0 6 0 ;No .39830 4 0 0 );国家自然科学基金面上项目 (No .39970 190;No .30 870 735 )

年　　份：2003

卷　　号：19

期　　号：6

起止页码：849-855

语　　种：中文

收录情况：BDHX、BDHX2000、CAS、CSCD、CSCD2011_2012、JST、RCCSE、ZGKJHX、核心刊

摘　　要：NF-κB is thought of as a genetic switch to control expressions of many target genes and directly participates in pathogenesis of infection, inflammation, stress, immunoresponse, cellular apoptosis, toxic shock and tumor as well as cell-cycle regulation and cell differentiation. The overactivation of NF-κB is intimately involved in many human diseases. Various therapeutic strategies against NF-κB, to date, include anti-inflammatory drugs, antioxidants, immunosuppressive agents, inhibitors of protease and proteasome, prostaglandings, nitric oxide, IL-10, microbial products, synthetic inhibitors, antisense oligonucleotides and decoy deoxyoligonucleotides. Studies are underway to develop NF-κB member-specific and cell type-specific drugs that can inhibit the activation of NF-κB only in target cells and that may become a novel way to treat the human diseases.

关 键 词：NF—Kappa  B  信号转导 炎症 肿瘤  

分 类 号：R363]